Skip to main content
SpringerLink
Log in

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed in any of the treatment cohorts. Amonafide and caracemide were well tolerated with no unexpected toxicities. One patient each died of pulmonary thromboembolism and sepsis with severe metabolic acidosis on the homoharringtonine arm. An additional 4 patients experienced grade 4 complications including myelosuppression, neurologic dysfunction, and respiratory failure. These severe and unexpected complications caused early termination of accrual to the homoharringtonine arm of the study. These agents have no activity in the treatment of advanced renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris DT: Hormonal therapy and chemotherapy of renal cell carcinoma. Seminars in Oncology 10(4):422–430, 1983

    Google Scholar 

  2. Hahn RG, Temkin NR, Sanlov RD, Perlis C, Wampler GL, Horton J et al.: Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Cancer Treat Rep 62:1093–1095, 1978

    Google Scholar 

  3. Hahn RG, Bauer M, Wolter J, Creech R, Bennett JM, Wampler G: Phase II study of single agent therapy with megestrol acetate, VP-16–213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. Cancer Treat Rep 63:513–515, 1979

    Google Scholar 

  4. Hahn RG, Begg CB, Davis TE: Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. Cancer Treat Rep 65:711–713, 1981

    Google Scholar 

  5. Earhart RH, Elson PJ, Rosenthal SN, Hahn RG, Slayton RE: Phase II study of PALA and AMSA in advanced renal cell carcinoma. Am J Clin Oncol 6:555–560, 1983

    Google Scholar 

  6. Elson PJ, Earhart RH, Kvols LK, Spigel R, Keller AM, Kias MS et al.: Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. Cancer Treat Rep 71:331–332, 1987

    Google Scholar 

  7. Elson PJ, Kvols LK, Vogl SE, Glower DJ, Hahn RG, Trump DL et al.: Phase II trials of 5-day vinblastine infusion (NSC 4 9842), L-alanosine (NSC 153353), acivisin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs 6:97–103, 1988

    Google Scholar 

  8. Trump DL, Elson PJ, Borden EC, Harris JE, Tuttle RL, Whisnsnt JK et al.: High-dose lymphoblastoid Interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Pilot Study. Cancer Treat Rep 71:165–169, 1987

    Google Scholar 

  9. Buzaid AC, Robertone A, Kisala, Salmon SE: Phase II study of interferon alfa-2a recombinant (Roferon-A) in metastatic renal cell carcinoma. J Clin Oncol 3:1083–1089, 1985

    Google Scholar 

  10. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA et al.: A randomized prospective assessment of recombinant leukocyte A interferon with and without aspirin in advanced renal cell adenocarcinoma. J Clin Oncol 9:2104–2109, 1991

    Google Scholar 

  11. DeKernion JB, Sarna G, Figlin R, Linder A, Smith RB: The treatment of renal cell carcinoma with human leukocyte alpha interferon. J Urol 130:1063–1066, 1983

    Google Scholar 

  12. Muss HB, Constanzi JJ, Leavitt R, Williams RD, Kemf RA, Pollard R et al.: Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 5:286–291, 1987

    Google Scholar 

  13. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU:Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3:1522–1528, 1985

    Google Scholar 

  14. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE: Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with longterm follow-up. J Clin Oncol 11:1368–1375, 1993

    Google Scholar 

  15. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI et al.: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11:661–670, 1993

    Google Scholar 

  16. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R: Inpatient continuous infusion interleukin-2 in 788 patients with cancer: the National Biotherapy Study Group experience. Cancer 71:2358–2370, 1993

    Google Scholar 

  17. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, de Kernion J: Concomitant administration of recombinant interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10:414–421, 1992

    CAS  PubMed  Google Scholar 

  18. Minutes of the Phase I working group and the Biochemical Modulators Advising Group. A U.S. Government publication, 1986

  19. National Cancer Institute Clinical Brochure. Caracemide (NSC253272). August 1983

  20. Raber MN, Adams F, Kavanagh J, Legha S, Dimery I, Krakoff I: Phase I trial of caracemide using bolus and infusional schedules. Cancer Treat Rep 71:349–352, 1987

    Google Scholar 

  21. Clinical Brochure: Homoharringtonine (NSC 141633) (IND19125), IDB, CTEP, DCT, NCI, Bethesda, MD, August 1982

  22. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ: Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63:813–817, 1989

    Google Scholar 

  23. Stewart JA, Cassileth PA, Bennett JM, O'Connell MJ: Continuous infusion homoharringtonine (NSC 141633) in refractory acute non-lymphocytic leukemia. An ECOG pilot study. Am J Clin Oncol 11:627–629, 1988

    Google Scholar 

  24. Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P: Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 6:1185–1188, 1992

    Google Scholar 

  25. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655, 1982

    CAS  PubMed  Google Scholar 

  26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:347–481, 1958

    Google Scholar 

  27. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Research 48:7310–7313, 1988

    Google Scholar 

  28. Feun LJ, Savaraj N, Landy H, Levin H, Lampidis T: Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. J Neurooncol 9:159–163, 1990

    Google Scholar 

  29. Runge-Morris MA, Kies MS, Vokes E, Blough R, Weidner L, Knop R, Rowland K: Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council study. Invest New Drugs 7:269–273, 1989

    Google Scholar 

  30. Lad T, Schor J, Mullane M, Carroll R, Chernicoff D, Blough R, Weidner L: Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Invest New Drugs10:27–28, 1992

    Google Scholar 

  31. Belani CP, Eisenberger M, Van Echo D, Hiponia D, Aisner J: Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat Rep 71:1099–1100, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gundersen Clinic, 1836 South Avenue, 54601, La Crosse, WI

    Robert S. Witte

  2. Division of Biostatistics, Dana Farber Cancer Institute, 02115, Boston, MA

    Peggy Hsieh

  3. Cleveland Clinic Cancer Center, Cleveland, OH

    Paul Elson

  4. Virginia Piper Cancer Institute, Minneapolis, MN

    Martin M. Oken

  5. University of Pittsburgh, Pittsburgh, PA, USA

    Donald L. Trump

Authors
  1. Robert S. Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peggy Hsieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Elson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin M. Oken
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Donald L. Trump
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Witte, R.S., Hsieh, P., Elson, P. et al. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Invest New Drugs 14, 409–413 (1996). https://doi.org/10.1007/BF00180819

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00180819

Key words

Search

Navigation